K Swedberg

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. ncbi request reprint [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]
    Karl Swedberg
    Sahlgrenska Academy, The Göteborg University, Goteborg, Sweden
    Rev Esp Cardiol 58:1062-92. 2005
  2. pmc Heart failure guidelines and prescribing in primary care across Europe
    Heidrun B Sturm
    Department of Clinical Pharmacology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    BMC Health Serv Res 5:57. 2005
  3. ncbi request reprint [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol]
    Karl Swedberg
    Medicinkliniken, Sahlgrenska Universitetssjukhuset Ostra, Goteborg
    Lakartidningen 100:2852-4. 2003
  4. ncbi request reprint Conclusions on the management of heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital, Gothernburg, Sweden
    J Renin Angiotensin Aldosterone Syst 5:S34-6. 2004
  5. ncbi request reprint Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  6. ncbi request reprint Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Circulation 105:1797-803. 2002
  7. ncbi request reprint Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:1303-8. 2005
  8. ncbi request reprint The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators
    K Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra Göteborg, Sweden
    J Am Coll Cardiol 35:398-404. 2000
  9. ncbi request reprint [Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Kardiol Pol 63:509-43; discussion 544-8. 2005
  10. pmc What can we learn from Europe?
    K Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Heart 91:ii21-3; discussion ii31, ii43-8. 2005

Detail Information

Publications80

  1. ncbi request reprint [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]
    Karl Swedberg
    Sahlgrenska Academy, The Göteborg University, Goteborg, Sweden
    Rev Esp Cardiol 58:1062-92. 2005
  2. pmc Heart failure guidelines and prescribing in primary care across Europe
    Heidrun B Sturm
    Department of Clinical Pharmacology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    BMC Health Serv Res 5:57. 2005
    ..National guideline recommendations might be a relevant factor. This study, therefore, explored variation of heart failure guideline recommendations in Europe...
  3. ncbi request reprint [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol]
    Karl Swedberg
    Medicinkliniken, Sahlgrenska Universitetssjukhuset Ostra, Goteborg
    Lakartidningen 100:2852-4. 2003
  4. ncbi request reprint Conclusions on the management of heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital, Gothernburg, Sweden
    J Renin Angiotensin Aldosterone Syst 5:S34-6. 2004
    ..It is desirable to use multiple agents for best results in patients with heart failure. New European Society of Cardiology guidelines on the management of heart failure are expected later this year...
  5. ncbi request reprint Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  6. ncbi request reprint Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Circulation 105:1797-803. 2002
    ..We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure...
  7. ncbi request reprint Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:1303-8. 2005
    ..Atrial fibrillation is common in patients with chronic heart failure (CHF). We analysed the risk associated with atrial fibrillation in a large cohort of patients with chronic heart failure all treated with a beta-blocker...
  8. ncbi request reprint The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators
    K Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra Göteborg, Sweden
    J Am Coll Cardiol 35:398-404. 2000
    ..To evaluate the dose response relationship of moxonidine on plasma concentration of norepinephrine during acute and chronic administration in patients with congestive heart failure (CHF)...
  9. ncbi request reprint [Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Kardiol Pol 63:509-43; discussion 544-8. 2005
  10. pmc What can we learn from Europe?
    K Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Heart 91:ii21-3; discussion ii31, ii43-8. 2005
    ..Similarly, the Swedish RIKS-HIA registry of acute myocardial infarction has increased the use of secondary preventive treatments...
  11. ncbi request reprint Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study
    B Houltz
    Department of Medicine, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Pacing Clin Electrophysiol 21:1044-57. 1998
    ..Patients developing TdP exhibited early during almokalant infusion a pronounced QT prolongation, increased QT dispersion, and marked morphological T wave changes...
  12. doi request reprint Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
    ..Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure...
  13. ncbi request reprint Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial
    Inger Ekman
    The Sahlgrenska Academy, Faculty of Health and Caring Sciences, Institute of Nursing, Goteborg University, Box 457, SE 405 30, Goteborg, Sweden
    Patient Educ Couns 61:348-53. 2006
    ..The objective was to describe perceptions about and adherence to regular medicines and study medication at baseline and study end in CHF patients participating in a clinical trial...
  14. doi request reprint Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy
    Kurt Boman
    Department of Medicine, Skellefteå County Hospital, Skellefteå, Umea University, Sweden
    Thromb Res 125:e46-50. 2010
    ..We aimed to study the effects of carvedilol or metoprolol on tissue plasminogen activator (tPA), its inhibitor PAI-1 and Von Willebrand factor (VWF) in patients with heart failure...
  15. ncbi request reprint Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Am Coll Cardiol 47:1997-2004. 2006
    ....
  16. ncbi request reprint Effects of the Ikr-blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study
    B Houltz
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Cardiovasc Drugs Ther 13:329-38. 1999
    ..To assess the efficacy of the Ikr-blocker almokalant attempting to convert chronic atrial tachyarrhythmias, and to find predictors of conversion, to sinus rhythm...
  17. ncbi request reprint Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000
    Maria Schaufelberger
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Eur Heart J 25:300-7. 2004
    ..To investigate if improved treatment of coronary heart disease and hypertension, the major causes of chronic heart failure (CHF), in the last 20 years has had an impact on the incidence of CHF and survival...
  18. ncbi request reprint Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
    Lars G Olsson
    Department of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Goteborg University, Goteborg, Sweden, and Department of Cardiology, La Pitie Salpetriere Hospital, Paris, France
    Eur J Heart Fail 9:795-801. 2007
    ..Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis...
  19. ncbi request reprint QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agent
    Birgitta Houltz
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Electrocardiol 35:201-12. 2002
    ..In conclusion, aberrant conduction is common during infusion of the I(kr)-blocker almokalant during AF, and seems to be more frequent in females and in patients with more advanced myocardial disease...
  20. ncbi request reprint Fibrinolytic capacity increases with age in healthy humans, while endothelium-dependent vasodilation is unaffected
    Thorarinn Gudnason
    Department of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 89:374-81. 2003
    ..008) in the age-quartiles, respectively. A similar significant age-related response was observed for tPA activity. We conclude that in healthy individuals there is an up-regulation of the fibrinolytic response by age...
  21. doi request reprint Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure
    Putte Abrahamsson
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Eur Heart J 30:338-45. 2009
    ..We explored the impact of having a hospital admission for an acute coronary syndrome (ACS) on the subsequent prognosis among patients with chronic heart failure (CHF)...
  22. ncbi request reprint Diagnostic and therapeutic algorithms in chronic heart failure
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Goteborg University, Gothenburg, Sweden
    Herz 31:877-90. 2006
    ..However, in some important aspects there can be differences in the interpretation of the evidence. A comparison of four major guideline documents was published recently...
  23. doi request reprint Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, SE 416 85 Goteborg, Sweden
    Eur J Heart Fail 12:75-81. 2010
    ..The study will include approximately 6500 patients and will continue until > or =1600 primary endpoints have occurred. The first patient was randomized in October 2006, and the study is expected to end in 2010...
  24. doi request reprint Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry
    Masoud Shafazand
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital Ostra, University of Gothenburg, S 416 85 Goteborg, Sweden
    Eur Heart J 30:671-8. 2009
    ..To investigate gender-specific trends in long-term mortality in patients hospitalized for heart failure (HF)...
  25. doi request reprint Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men
    Annika Rosengren
    Department of Medicine, Sahlgrenska University Hospital Ostra, Göteborg SE 416 85, Sweden
    Eur Heart J 30:1113-20. 2009
    ..Obesity is a recognized risk factor for atrial fibrillation (AF), partly because of the association between body mass index (BMI) and atrial volume. We aimed to determine whether other factors relating to body size were related to AF...
  26. ncbi request reprint Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:778-93. 2005
    ..The aim of this study is to investigate, using a systematic literature review, the utility of the 6MWT as a measure of the effectiveness of treatment in randomized controlled trials of heart failure...
  27. ncbi request reprint ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality
    P Johanson
    Clinical Experimental Research Laboratory, Sahlgrenska University, Hospital Ostra, SE 416 85 Goteborg, Sweden
    Ann Noninvasive Electrocardiol 6:198-202. 2001
    ..Recurrent ST-segment elevation has been shown to reflect cyclic disturbances in perfusion...
  28. ncbi request reprint Skeletal muscle characteristics, muscle strength and thigh muscle area in patients before and after cardiac transplantation
    M Schaufelberger
    Department of Medicine, Sahlgrenska University Hospital, Ostra, Goteborg University, Goteborg, Sweden
    Eur J Heart Fail 3:59-67. 2001
    ..Patients with chronic heart failure demonstrate several skeletal muscle abnormalities. The underlying mechanisms are unclear. After cardiac transplantation, cardiac function is restored, but exercise capacity is still impaired...
  29. doi request reprint Home care as an option in worsening chronic heart failure -- a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness
    Harshida Patel
    Institute of Health and Care Sciences, Sahlgrenska Academy, Sweden
    Eur J Heart Fail 10:675-81. 2008
    ..Worsening chronic heart failure (CHF) is largely characterized by frequent hospital admissions and the need for specialist care...
  30. ncbi request reprint Heart failure in an elite soccer player
    M A Börjesson
    Multidisciplinary Pain Center, Department of Medicine, Sahlgrenska University Hospital Ostra, 41685 Goteborg, Sweden
    Int J Sports Med 24:101-3. 2003
    ..Finally, our patient is an excellent example of the complete recovery that may follow successful radiofrequency catheter ablation, performed promptly once the correct diagnosis has been confirmed...
  31. doi request reprint Successful treatment of heart failure with devices requires collaboration
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Eur J Heart Fail 10:1229-35. 2008
    ..Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities...
  32. ncbi request reprint [Safe diagnosis in acute phase with T-proBNP. Heart failure and acute coronary syndrome can be identified very early]
    Jaana Javadzadeh
    Sahlgrenska Universitetssjukhuset Ostra, Goteborg
    Lakartidningen 105:616-9. 2008
  33. ncbi request reprint Standard medication information is not enough: poor concordance of patient and nurse perceptions
    Inger Ekman
    Institute of Health and Care Sciences, The Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    J Adv Nurs 60:181-6. 2007
    ..This paper is a report of a study to describe patient and nurse perceptions of patient satisfaction with information about the medicines at two heart failure clinics after medication up-titration and information-giving...
  34. doi request reprint A pilot study of salt and water restriction in patients with chronic heart failure
    Henriette Philipson
    Department of Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Scand Cardiovasc J 44:209-14. 2010
    ..Urine sodium excretion was measured on three consecutive days and para-aminobenzoic acid was used to secure urine collection. Individual dietary recommendations were provided...
  35. ncbi request reprint Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  36. ncbi request reprint Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur J Heart Fail 9:1128-35. 2007
    ..In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months...
  37. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  38. ncbi request reprint The safety of amiodarone in patients with heart failure
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    J Card Fail 13:340-5. 2007
    ..Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure...
  39. ncbi request reprint Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:901-9. 2007
    ..We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET...
  40. ncbi request reprint Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
    Nathaniel M Hawkins
    Stobhill Hospital, Glasgow, UK
    Eur J Heart Fail 9:510-7. 2007
    ..The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood...
  41. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
    ..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
  42. ncbi request reprint Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Eur J Heart Fail 5:659-67. 2003
    ....
  43. ncbi request reprint Heart failure management. Interview with Karl Swedberg
    Karl Swedberg
    Timely Top Med Cardiovasc Dis 11:E1. 2007
  44. ncbi request reprint The CHARM program: study design leads to findings of clinical and public health importance
    Charles H Hennekens
    Florida Atlantic University, Boca Raton, Florida, and Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Cardiovasc Pharmacol Ther 12:124-6. 2007
    ..Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older...
  45. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  46. ncbi request reprint Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Eur J Heart Fail 4:321-9. 2002
    ..The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET...
  47. ncbi request reprint Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
    Milton Packer
    Division of Circulatory Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Circulation 106:920-6. 2002
    ..Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone...
  48. ncbi request reprint Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  49. ncbi request reprint VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
    Eric J Velazquez
    Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Eur J Heart Fail 5:537-44. 2003
    ....
  50. doi request reprint Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
    R A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom Faculty of Medicine, University of Glasgow, United Kingdom
    Eur J Heart Fail 10:157-63. 2008
    ..The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together...
  51. ncbi request reprint Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  52. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    John J V McMurray
    University of Glasgow, Glasgow, UK
    Lancet 362:767-71. 2003
    ..We aimed to find out whether these drugs improve clinical outcome...
  53. ncbi request reprint Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction
    Norman C Wang
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    JAMA 299:2656-66. 2008
    ..Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied...
  54. doi request reprint Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study
    Eldrin F Lewis
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 29:748-56. 2008
    ..We sought to assess the incidence of and prognostic factors for heart failure (HF) hospitalization among survivors of high-risk acute myocardial infarction (MI)...
  55. pmc Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen NV, Denmark
    Heart 93:968-73. 2007
    ..Beta blocker treatment may worsen glucose metabolism...
  56. ncbi request reprint Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge
    Nasrin K Khan
    University of Hull, Kingston upon Hull, United Kingdom
    Eur J Heart Fail 9:491-501. 2007
    ..Most patients suspected of having heart failure (HF) will get a 12-lead electrocardiogram (ECG) but its utility for excluding HF or assisting in its management has rarely been investigated...
  57. ncbi request reprint Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, G12 8QQ, UK
    Circulation 110:3281-8. 2004
  58. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
    Eur J Heart Fail 7:710-21. 2005
    ..These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines...
  59. ncbi request reprint Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  60. ncbi request reprint Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure
    Salim Yusuf
    Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Canada
    Circulation 112:48-53. 2005
    ....
  61. ncbi request reprint Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
    Andrea Di Lenarda
    Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    Eur J Heart Fail 7:640-9. 2005
    ..metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol...
  62. ncbi request reprint Gender makes a difference in the description of dyspnoea in patients with chronic heart failure
    Inger Ekman
    Faculty of Health and Caring Sciences, Institute of Nursing, The Sahlgrenska Academy at Goteborg University, Box 457, Göteborg SE 405 30, Sweden
    Eur J Cardiovasc Nurs 4:117-21. 2005
    ..Dyspnoea is a common symptom of chronic heart failure (CHF). In the community setting, patients with CHF are most often women...
  63. ncbi request reprint Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience
    Mika Lehto
    Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
    Eur Heart J 26:350-6. 2005
    ..The present study aimed to determine the frequency and the impact on clinical outcome of atrial fibrillation (AF) in patients with acute myocardial infarction (AMI) and left ventricular dysfunction...
  64. ncbi request reprint Symptoms in patients with heart failure are prognostic predictors: insights from COMET
    Inger Ekman
    Institute of Nursing, Sahlgrenska Academy at Goteborg University, SE 405 30 Goteborg, Sweden
    J Card Fail 11:288-92. 2005
    ....
  65. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ....
  66. ncbi request reprint Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    Am Heart J 149:370-6. 2005
    ..Beta-blockers with different receptor bindings reduce mortality in patients with chronic heart failure. We compared the effects of the beta1-blocker metoprolol tartrate and the beta1-, beta2-, and alpha1-blocker carvedilol...
  67. ncbi request reprint [Diagnosis and treatment of acute heart failure. Guidelines of the European Society of Cardiology]
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
    Kardiol Pol 63:143-86; discussion 187-9. 2005
  68. ncbi request reprint Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
    James B Young
    Division of Medicine, The Cleveland Clinic Foundation and Kaufman Center for Heart Failure, 9500 Euclid Avenue T 13, Cleveland, OH 44195, USA
    Circulation 110:2618-26. 2004
    ..CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program...
  69. ncbi request reprint Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
    Mattie J Lenzen
    Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
    Eur Heart J 26:2706-13. 2005
    ..Evidence-based medicine and clinical guidelines are based on the results of randomized controlled trials. Therefore, we investigated how patients who fulfilled the enrolment criteria of randomized trials were treated in real life...
  70. ncbi request reprint Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  71. ncbi request reprint International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey
    Mitja Lainscak
    Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia
    Eur J Heart Fail 9:292-9. 2007
    ..This may reflect a lack of adequate organisation of care or co-morbidity contra-indicating therapy...
  72. ncbi request reprint Treatment of chronic heart failure: a comparison between the major guidelines
    John McMurray
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Eur Heart J 27:1773-7. 2006
    ..Possible explanations for discrepancies between the guidelines are discussed. Future approaches that might clarify the grade of evidence allocated and class of recommendation made are also described...
  73. ncbi request reprint Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Karl Swedberg
    Eur Heart J 25:357-8. 2004
  74. ncbi request reprint Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:985-91. 2006
    ..Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain...
  75. ncbi request reprint A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  76. ncbi request reprint Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  77. ncbi request reprint A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  78. ncbi request reprint Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure
    Catherine Demers
    McMaster University, Hamilton, Ontario, Canada
    JAMA 294:1794-8. 2005
    ..Angiotensin-converting enzyme (ACE) inhibitors reduce the risk of myocardial infarction (MI), but it is not known whether angiotensin receptor blockers have the same effect...
  79. ncbi request reprint Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
    ..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program...
  80. ncbi request reprint Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
    Eur Heart J 26:384-416. 2005